A 12-week Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
Public ClinicalTrials.gov record NCT01052194. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A 12-week, Double-blind, Randomized, Parallel-group, Placebo-controlled Study of 4 Doses of VX-509 in Subjects With Active Rheumatoid Arthritis
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study is designed to evaluate safety and assess initial efficacy of VX-509, a JAK3 inhibitor, for treatment of subjects with active RA. This study will assess the clinical response of 4 doses of VX-509 compared to placebo when administered for 12 weeks to patients with active RA. The study will also evaluate the safety and tolerability of VX-509 compared to placebo when administered for 12 weeks to subjects with active RA.
Study identification
- NCT ID
- NCT01052194
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 206 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Feb 2010 (Type not available)
- Primary completion
- Jul 2011 (Actual)
- Completion
- Jul 2011 (Actual)
- Last update posted
- Dec 13, 2012
2010 – 2011
United States locations
- U.S. sites
- 18
- U.S. states
- 15
- U.S. cities
- 17
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Not listed | Birmingham | Alabama | 35216 | — |
| Not listed | Huntsville | Alabama | 35801 | — |
| Not listed | Peoria | Arizona | 85381 | — |
| Not listed | La Mesa | California | 97942 | — |
| Not listed | Trumbull | Connecticut | 06611 | — |
| Not listed | Tampa | Florida | 33612 | — |
| Not listed | Tampa | Florida | 33614 | — |
| Not listed | Venice | Florida | 34292 | — |
| Not listed | Decatur | Georgia | 30033 | — |
| Not listed | Worcester | Massachusetts | 01610 | — |
| Not listed | St Louis | Missouri | 63141 | — |
| Not listed | Charlotte | North Carolina | 28210 | — |
| Not listed | Oklahoma City | Oklahoma | 73104 | — |
| Not listed | Duncansville | Pennsylvania | 16635 | — |
| Not listed | Charleston | South Carolina | 29406 | — |
| Not listed | Dallas | Texas | 75235 | — |
| Not listed | Spokane | Washington | 99204 | — |
| Not listed | Clarksburg | West Virginia | 26301 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 30 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01052194, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 13, 2012 · Synced Oct 18, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT01052194 live on ClinicalTrials.gov.